This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Guillaume, V. Articles by Wild, T. F. Search for Related Content PubMed PubMed Citation Articles by Guillaume, V. Articles by Wild, T. F.

Antibody Prophylaxis and Therapy against Nipah Virus Infection in Hamsters

V. Guillaume,^1,3 H. Contamin,⁴ P. Loth,⁴ I. Grosjean,³ M. C. Georges Courbot,⁴ V. Deubel,^4, R. Buckland,^1,3 and T. F. Wild^2,3*

Molecular Basis of Paramyxovirus Entry,¹ Immunobiology of Viral Infections, INSERM, U404, Lyon, F-69365 France,² IFR 128, BioScience Lyon-Gerland, Université Claude Bernard Lyon 1, Lyon, F-69365 France,³ UBIVE, Institut Pasteur, CERVI, IFR 128, Lyon, France⁴

Received 28 September 2005/ Accepted 22 November 2005

Nipah virus (NiV), a member of the Paramyxoviridae family, causes a zoonotic infection in which the reservoir, the fruit bat, may pass the infection to pigs and eventually to humans. In humans, the infection leads to encephalitis with >40 to 70% mortality. We have previously shown that polyclonal antibody directed to either one of two glycoproteins, G (attachment protein) or F (fusion protein), can protect hamsters from a lethal infection. In the present study, we have developed monoclonal antibodies (MAbs) to both glycoproteins and assessed their ability to protect animals against lethal NiV infection. We show that as little as 1.2 µg of an anti-G MAb protected animals, whereas more than 1.8 µg of anti-F MAb was required to completely protect the hamsters. High levels of either anti-G or anti-F MAbs gave a sterilizing immunity, whereas lower levels could protect against a fatal infection but resulted in an increase in anti-NiV antibodies starting 18 days after the viral challenge. Using reverse transcriptase PCR, the presence of NiV in the different organs could not be observed in MAb-protected animals. When the MAbs were given after infection, partial protection (50%) was observed with the anti-G MAbs when the animals were inoculated up to 24 h after infection, but administration of the anti-F MAbs protected some animals (25 to 50%) inoculated later during the infection. Our studies suggest that immunotherapy could be used for people who are exposed to NiV infections.

Present address: Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, People's Republic of China.

This article has been cited by other articles:

• Mungall, B. A., Middleton, D., Crameri, G., Bingham, J., Halpin, K., Russell, G., Green, D., McEachern, J., Pritchard, L. I., Eaton, B. T., Wang, L.-F., Bossart, K. N., Broder, C. C. (2006). Feline Model of Acute Nipah Virus Infection and Protection with a Soluble Glycoprotein-Based Subunit Vaccine. J. Virol. 80: 12293-12302 [Abstract] [Full Text]  
• Guillaume, V., Aslan, H., Ainouze, M., Guerbois, M., Fabian Wild, T., Buckland, R., Langedijk, J. P. M. (2006). Evidence of a Potential Receptor-Binding Site on the Nipah Virus G Protein (NiV-G): Identification of Globular Head Residues with a Role in Fusion Promotion and Their Localization on an NiV-G Structural Model.. J. Virol. 80: 7546-7554 [Abstract] [Full Text]  
• Weingartl, H. M., Berhane, Y., Caswell, J. L., Loosmore, S., Audonnet, J.-C., Roth, J. A., Czub, M. (2006). Recombinant Nipah Virus Vaccines Protect Pigs against Challenge.. J. Virol. 80: 7929-7938 [Abstract] [Full Text]